



OncoSwitch generates DNA “switches” that only turn on genes in tumors

OncoSwitch Team



Malika Gallyamova
(CEO) [in](#)

AI & CS, Strategy and Company Leadership



Vitalii Volkov
(CTO) [in](#)

AI & CS + MD, Senior Bioinformatician



Nadav Ahituv
(CSO) [in](#)

Director, Institute for Human Genetics, UCSF



Dmitry Mikhailov
(Advisor) [in](#)

AI Research Expert at the United Nations

The problem

- No tumor-specific control
- Off-target activation
- Tumour heterogeneity


What we solve

- ✓ Tumour selectivity
- ✓ Multi-signal control logic
- ✓ Adaptive design

Technology

- AI designs switch candidates
- Lab tests in parallel (MPRA)
- Model learns from results

Design → Test → Learn → Improve



Business Model



Paid pilots

Year 1-2



SaaS / Platform access

Year 2-5




Licenses

Year 3-5+

Where DNA switches matter most

- CAR-T / TCR control
- Tumor-specific safety switches
- Inducible cytokine expression
- Suicide / vulnerability genes
- CRISPR control



Roadmap

- 01 Platform setup
- 02 Model training
- 03 MVP & pilots
- 04 Licensing

Raising

24 months

\$8M
(Seed)

Use of Funds

